DK1879612T3 - Anvendelse af native peptider og deres optimerede derivater til vaccination - Google Patents

Anvendelse af native peptider og deres optimerede derivater til vaccination

Info

Publication number
DK1879612T3
DK1879612T3 DK06743108T DK06743108T DK1879612T3 DK 1879612 T3 DK1879612 T3 DK 1879612T3 DK 06743108 T DK06743108 T DK 06743108T DK 06743108 T DK06743108 T DK 06743108T DK 1879612 T3 DK1879612 T3 DK 1879612T3
Authority
DK
Denmark
Prior art keywords
vaccination
optimized
native
peptides
native peptides
Prior art date
Application number
DK06743108T
Other languages
English (en)
Inventor
Kostantinos Kosmatopoulos
Original Assignee
Vaxon Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxon Biotech filed Critical Vaxon Biotech
Application granted granted Critical
Publication of DK1879612T3 publication Critical patent/DK1879612T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
DK06743108T 2005-05-09 2006-05-09 Anvendelse af native peptider og deres optimerede derivater til vaccination DK1879612T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05290984 2005-05-09
PCT/EP2006/005325 WO2006120038A2 (en) 2005-05-09 2006-05-09 Use of native peptides and their optimized derivatives for vaccination

Publications (1)

Publication Number Publication Date
DK1879612T3 true DK1879612T3 (da) 2009-07-20

Family

ID=37396914

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06743108T DK1879612T3 (da) 2005-05-09 2006-05-09 Anvendelse af native peptider og deres optimerede derivater til vaccination

Country Status (13)

Country Link
US (2) US8663645B2 (da)
EP (1) EP1879612B1 (da)
JP (1) JP5435938B2 (da)
CN (1) CN101171032B (da)
AT (1) ATE427117T1 (da)
BR (1) BRPI0608768B1 (da)
CA (1) CA2606871C (da)
DE (1) DE602006006046D1 (da)
DK (1) DK1879612T3 (da)
ES (1) ES2323895T3 (da)
PL (1) PL1879612T3 (da)
PT (1) PT1879612E (da)
WO (1) WO2006120038A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010010A1 (en) 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
CN102153658A (zh) * 2011-01-19 2011-08-17 上海科医联创生物科技有限公司 肿瘤抗原、dc肿瘤疫苗及其制备方法
CN108434440B (zh) * 2011-09-06 2022-08-23 新加坡科技研究局 多肽疫苗
JP6925980B2 (ja) 2015-05-13 2021-08-25 アジェナス インコーポレイテッド がんの処置および予防のためのワクチン
EP3400959A1 (en) * 2017-05-09 2018-11-14 Vaxon Biotech Use of a vaccine targeting a cryptic tert epitope, for treating cancer in a hla-a*0201-positive patient having a non-immunogenic tumor expressing tert
EP3400954A1 (en) * 2017-05-09 2018-11-14 Vaxon Biotech Vaccine targeting a cryptic tert epitope, for treating lung cancer in a hla-a*0201-positive never-smoker or light-former smoker patient
US20200147195A1 (en) * 2017-05-26 2020-05-14 The Wistar Institute Of Anatomy And Biology Dtert vaccines and methods of treatment using the same
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001241533A1 (en) * 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
FR2837837B1 (fr) * 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
FR2838742B1 (fr) * 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2

Also Published As

Publication number Publication date
BRPI0608768B1 (pt) 2019-08-20
EP1879612A2 (en) 2008-01-23
DE602006006046D1 (de) 2009-05-14
US20080254051A1 (en) 2008-10-16
ES2323895T3 (es) 2009-07-27
WO2006120038A2 (en) 2006-11-16
CN101171032A (zh) 2008-04-30
US20140178421A1 (en) 2014-06-26
CA2606871A1 (en) 2006-11-16
EP1879612B1 (en) 2009-04-01
BRPI0608768A2 (pt) 2010-01-26
WO2006120038A3 (en) 2007-07-19
PL1879612T3 (pl) 2009-08-31
JP2008540483A (ja) 2008-11-20
JP5435938B2 (ja) 2014-03-05
ATE427117T1 (de) 2009-04-15
CN101171032B (zh) 2012-02-29
PT1879612E (pt) 2009-06-30
US8663645B2 (en) 2014-03-04
CA2606871C (en) 2014-06-03

Similar Documents

Publication Publication Date Title
DK1879612T3 (da) Anvendelse af native peptider og deres optimerede derivater til vaccination
CY1118372T1 (el) Νεα μεθοδος και συνθεσεις
MX2020002183A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos.
WO2009026465A3 (en) Composition and methods of making and using influenza proteins
PH12015502180A1 (en) Wt1-antigen peptide conjugate vaccine
BRPI0817299A8 (pt) vacinas e componentes de vacina para inibição de células microbianas
ATE404225T1 (de) Radiofluorierte peptide
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
EA201990071A1 (ru) Композиция пептидной вакцины
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
ATE426412T1 (de) Adjuvante influenza-vakzine
ATE539089T1 (de) Cyclische rezeptor-assoziierte-proteine (rap)- peptide
EA200701128A1 (ru) Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы
ECSP066912A (es) Formulaciones de dispersiones sólidas de acetato de bazedoxifeno
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
MX2017010335A (es) Inmunoconjugados para la inducción específica de citotoxicidad de células t contra una célula blanco.
DK1987063T3 (da) Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
NZ732301A (en) Peptide compound, preparation method therefor, and application thereof
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus
IN2015DN03925A (da)
WO2007127372A3 (en) Genetic adjuvants for viral vaccines